Compare ERNA & KXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERNA | KXIN |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | China |
| Employees | N/A | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 7.0M |
| IPO Year | 2021 | N/A |
| Metric | ERNA | KXIN |
|---|---|---|
| Price | $3.28 | $5.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 548.8K | 51.0K |
| Earning Date | 05-07-2026 | 11-26-2019 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $582,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.11 |
| 52 Week High | $15.88 | $22.00 |
| Indicator | ERNA | KXIN |
|---|---|---|
| Relative Strength Index (RSI) | 30.25 | 54.49 |
| Support Level | $0.23 | $5.30 |
| Resistance Level | $7.94 | $5.95 |
| Average True Range (ATR) | 0.74 | 0.43 |
| MACD | -0.18 | 0.01 |
| Stochastic Oscillator | 1.21 | 51.17 |
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.